Comprehensive Dermatologic Drug Therapy

Stephen E Wolverton, Jashin J. Wu (Autoren)

Buch | Hardcover

858 Seiten

2020 | 4th edition
Elsevier - Health Sciences Division (Verlag)
978-0-323-61211-1 (ISBN)

Infos

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you're likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You'll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.



Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions.
Covers the best uses for new biologic therapeutics.
Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors.
Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.
Features a highly detailed, disease-specific index, as well as purchase information for major drugs.
Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Inhalt

Part I: Introduction

1 Basic Principles of Pharmacology

2 Principles for Maximizing the Safety of Dermatologic Drug Therapy

3 Polymorphisms: Why Individual Drug Responses Vary

4 Adherence to Drug Therapy

5 Medical Decision Making

Part II: Important Drug Regulatory Issues

6 The FDA Drug Approval Process

7 Pharmacovigilance: Verifying that Drugs Remain Safe

8 Drugs Taken Off the Market: Important Lessons Learned

Part III: Systemic Drugs for Infectious Diseases

9 Systemic Antibacterial Agents

10 Systemic Antifungal Agents

11 Systemic Antiviral Agents

12 Systemic Antiparasitic Agents

Part IV: Systemic Immunomodulatory Drugs

13 Systemic Corticosteroids

14 Methotrexate

15 Azathioprine

16 Mycophenolates

17 Cyclosporine

18 Phosphodiesterase-4 and Janus Kinase Inhibitors

19 Cytotoxic Agents

20 Dapsone

21 Antimalarial Agents

22 Systemic Retinoids

Part V: Drugs Used in Conjunction with UV or Visible Light

23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

24 Extracorporeal Photochemotherapy (Photopheresis)

25 Photodynamic Therapy

Part VI: Biologic Therapeutics

26 Tumor Necrosis Factor Inhibitors

27 Interleukin 12/23 Inhibitors

28 Interleukin 17 Inhibitors

29 Interleukin 23 Inhibitors

30 Rituximab

31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

Part VII: Miscellaneous Systemic Drugs

32 Antihistamines

33 Vasoactive and Antiplatelet Agents

34 Antiandrogens and Androgen Inhibitors

35 Psychotropic Agents

36 Intravenous Immunoglobulin Therapy

37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events

38 Hedgehog Pathway Inhibitors

39 Drugs for the Skinternist

40 Miscellaneous Systemic Drugs

Part VIII: Topical Drugs for Infectious Diseases

41 Topical Antibacterial Agents

42 Topical Antifungal Agents

43 Topical and Intralesional Antiviral Agents

44 Topical Antiparasitic Agents

Part IX: Topical Immunomodulatory Drugs

45 Topical Corticosteroids

46 Topical Retinoids

47 Topical and Intralesional Chemotherapeutic Agents

48 Topical Calcineurin Inhibitors

49 Topical Vitamin D3

Part X: Miscellaneous Topical Drugs

50 Sunscreens

51 Therapeutic Shampoos

52 ?-Hydroxy Acids

53 Chemical Peels

54 Products for the Care of Chronic Wounds

55 Agents Used for Treatment of Hyperkeratosis

56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents

57 Miscellaneous Topical Agents

Part XI: Injectable and Mucosal Routes of Drug Administration

58 Local Anesthetics

59 Injectable Dermal and Subcutaneous Fillers

60 Botulinum Toxin Injections

61 Oral Mucosal Therapeutics

Part XII: Major Adverse Effects From Systemic Drugs

62 Hepatotoxicity of Dermatologic Drug Therapy

63 Hematologic Toxicity of Drug Therapy

64 Drug-induced Malignancy

65 Dermatologic Drugs During Pregnancy and Lactation

66 Drug Interactions

67 Cutaneous Drug Reactions With Systemic Features

Part XIII: Special Pharmacology and Therapeutics Topics

68 Informed Consent and Risk Management

69 Compounding in Dermatology

70 Dermatologic Drug Therapy in Children

Appendix I Core Questions for Understanding Systemic Dermatologic Drugs

Appendix II The Most Potentially Serious Drug Interactions

Produkt-Details

• Erscheinungsdatum: 04.02.2020
• Verlagsort: Philadelphia
• Sprache: englisch
• Maße: 216 x 276 mm
• Gewicht: 2540 g
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Dermatologie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Physiologie
• ISBN-10: 0-323-61211-3 / 0323612113
• ISBN-13: 978-0-323-61211-1 / 9780323612111
• Zustand: Neuware